8-K: LivaNova Prices $300 Million Convertible Senior Notes Offering and Enters Capped Call Transactions

LivaNova PLC has announced the pricing of a $300 million private offering of convertible senior notes due in 2029, along with related capped call transactions and a plan to repurchase existing notes.

Summary

• LivaNova has priced a private offering of $300 million in convertible senior notes due in 2029.
• The notes will bear interest at 2.50% per year, payable semi-annually.
• The company has granted an option to initial purchasers to buy an additional $45 million in notes.
• Net proceeds are expected to be approximately $289.3 million, or $333 million if the option is fully exercised.
• The notes are convertible into LivaNova ordinary shares at an initial conversion rate of 14.4085 shares per $1,000 principal amount, equivalent to a conversion price of approximately $69.40 per share.
• LivaNova has entered into capped call transactions to mitigate potential dilution from the note conversions.
• The cap price of the capped call transactions is initially $94.2840 per share.
• LivaNova also plans to repurchase $230 million of its existing 3.00% Cash Exchangeable Senior Notes due 2025 for $270.5 million.
• The net proceeds will be used to pay for the capped call transactions, the note repurchases, and for general corporate purposes.

Sentiment

Score: 7

Explanation: The document indicates a strategic financial move by LivaNova to raise capital and manage debt. While there are potential risks associated with the market activity and dilution, the overall tone is positive, suggesting a proactive approach to financial management.

Positives

• The offering provides LivaNova with a significant amount of capital, potentially up to $333 million if the option is fully exercised.
• The capped call transactions are designed to mitigate potential dilution from the conversion of the notes.
• The repurchase of existing notes will reduce the company's debt obligations.
• The conversion premium of 32.5% suggests a positive outlook on the company's future share price.

Negatives

• The company is taking on additional debt with the issuance of the convertible notes.
• The repurchase of the 2025 notes will cost the company $270.5 million for $230 million of debt, indicating a premium paid to retire the debt.
• The market price of LivaNova's ordinary shares could be affected by the hedging activities of the option counterparties.

Risks

• The market price of LivaNova's ordinary shares could be volatile due to the hedging activities related to the capped call transactions and note repurchases.
• The company may not be able to repurchase all of the targeted $230 million of the 2025 notes.
• The conversion of the notes could dilute existing shareholders if the share price rises significantly.
• There is no guarantee that the company will be able to redeem the notes at its option.

Future Outlook

LivaNova expects to use the net proceeds from the offering for capped call transactions, note repurchases, and general corporate purposes. The company also anticipates potential market activity from counterparties hedging their positions.

Industry Context

This announcement is typical for a medical technology company seeking to raise capital and manage its debt. The use of convertible notes and capped call transactions is a common strategy to balance funding needs with potential dilution concerns. The repurchase of existing debt is also a common practice to optimize the capital structure.

Comparison to Industry Standards

• The use of convertible notes is a common financing method for companies in the medical technology sector, similar to offerings by companies like Medtronic and Boston Scientific.
• The 2.50% interest rate on the convertible notes is relatively low, reflecting the current interest rate environment and LivaNova's credit profile.
• The capped call transactions are a standard practice to mitigate dilution, similar to strategies employed by other companies issuing convertible debt.
• The repurchase of existing debt at a premium is not uncommon when companies seek to reduce their overall debt burden or manage upcoming maturities, similar to actions taken by other companies in the sector.

Stakeholder Impact

• Shareholders may experience potential dilution if the notes are converted.
• Noteholders will receive interest payments and have the option to convert their notes into shares.
• The company's financial position will be impacted by the new debt and the repurchase of existing debt.
• The market price of LivaNova's shares may be affected by the hedging activities of the option counterparties.

Next Steps

• The sale of the notes is expected to settle on March 8, 2024.
• LivaNova will apply for the listing of the notes on The International Stock Exchange in Guernsey.
• The company will negotiate the repurchase of the 2025 cash exchangeable senior notes.
• LivaNova will enter into agreements to terminate a portion of the existing capped call transactions related to the repurchased notes.

Key Dates

Keywords

convertible notes, capped call, debt financing, note repurchase, LivaNova, medical technology, senior notes, dilution, hedging, capital raise